Interim Analysis of Phase III REGENERATE: Obeticholic Acid vs Placebo for NASH

April 10-14, 2019; Vienna, Austria
Obeticholic acid showed significant, dose-dependent improvement in the primary endpoint of fibrosis improvement with no worsening of NASH in this interim analysis of a large randomized trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 195 KB
Released: April 16, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Educational grant provided by:
Gilead Sciences

Related Content

Expert commentary on the evolving understanding of NAFLD and NASH pathobiology and promising progress toward effective treatment strategies

Manal F. Abdelmalek, MD, MPH Released: October 4, 2019

Expert overview of recommendations on screening, diagnosis, and treatment of nonalcoholic steatohepatitis (NASH).

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Program Director
Philip N. Newsome, PhD, FRCPE
Released: August 21, 2019

Audio from Clinical Care Options: Zobair Younossi, MD, discusses the clinical impact of the most important NAFLD/NASH data from EASL 2019 in Vienna.

Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: May 2, 2019

April 10-14, 2019; Vienna, Austria: Expert faculty members summarize key viral hepatitis studies from this important annual conference.

Nancy Reau, MD Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Stefan Zeuzem, MD Released: April 30, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?